{"id":"W4295837229","doi":"10.1016/j.annonc.2022.07.1500","title":"1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Pfizer Pharmaceuticals; Genentech; Sierra Oncology; Astellas Pharma; Menarini Silicon Biosystems; Vertex Pharmaceuticals; Merck Sharp and Dohme; Eisai; National Evidence-based Healthcare Collaborating Agency; Sanofi; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Taxane; Clinical endpoint; Olaparib; Primary tumor; Progression-free survival; Hormonal therapy; Population; Cancer; Breast cancer; Chemotherapy; Clinical trial; Genetics; Metastasis; Gene; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002106688,0.0002635992,0.0003768415,0.0002264573,0.0001504355,0.0005057142,0.0002468979,0.0003663265,0.006563453],"category_scores_gemma":[0.0003071809,0.0001087806,0.0002493599,0.0002523448,0.0002497644,0.000259444,0.0001627799,0.0006831331,0.0006914235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005085798,"about_ca_system_score_gemma":0.0004164564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006120253,"about_ca_topic_score_gemma":0.001744401,"domain_scores_codex":[0.9999098,0.00001694268,0.000004950664,0.00001817019,0.00002183386,0.00002832304],"domain_scores_gemma":[0.9999344,0.00001651265,0.00001219354,0.000004675069,0.000008133824,0.00002416013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.04503245,0.002314687,0.01597055,0.0006714196,0.0007398785,0.002413385,0.0001231383,0.004966179,0.466971,0.003990715,0.01072962,0.446077],"study_design_scores_gemma":[0.03258809,0.1291617,0.236449,0.0003581706,0.002782193,0.02820476,0.000515021,0.02857563,0.396106,0.01012854,0.1348479,0.0002830244],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782598,0.005778518,0.0008204134,0.002153888,0.0001604776,0.0001029522,0.001019223,0.0001680076,0.01153673],"genre_scores_gemma":[0.9945023,0.001048647,0.0005492065,0.0003652956,0.00003953571,0.00002947437,0.0006220157,0.000015485,0.002828134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006563453,"threshold_uncertainty_score":0.02195692,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1078163210474281,"score_gpt":0.3853297899271207,"score_spread":0.2775134688796926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}